Bremelanotide

human trialChange in Female Sexual Distress Scale–Desire/Arousal/Orgasm item 13 from baseline to end ranged from −1.4 to −1.7 for patients who received bremelanotide during the core phase⁶

human trialPremenopausal women treated with bremelanotide exhibited sustained improvements in hypoactive sexual desire disorder symptoms⁶

human trialBremelanotide 1.75 mg SC significantly improves sexual desire and reduces distress in premenopausal women with HSDD compared to placebo⁷

human trialFSFI desire score change of +0.35 for bremelanotide vs baseline with p<.001⁷

human trialFSDS-DAO distress change of -0.33 for bremelanotide vs baseline with p<.001⁷

human trialStudy 301 desire change of +0.30 for bremelanotide vs baseline with p<.001⁷

human trialStudy 302 desire change of +0.42 for bremelanotide vs baseline with p<.001⁷

human trialPT-141 has completed Phase 3 clinical trials and received FDA approval⁷

human trialIn two identical Phase 3 randomized controlled trials (RECONNECT studies) involving 1,247 premenopausal women, there was statistically significant improvement in sexual desire (integrated studies: 0.35 point increase, P<.001)⁸

human trialIn two identical Phase 3 randomized controlled trials (RECONNECT studies) involving 1,247 premenopausal women, there was statistically significant reduction in distress related to low sexual desire (integrated studies: -0.33 point decrease, P<.001)⁸

human trialIn one randomized controlled trial, intranasal bremelanotide 10 mg in 342 men with sildenafil-refractory erectile dysfunction showed 33.5% positive response vs 8.5% placebo (p=0.03)⁸

human trialData from clinical trials demonstrated a significant change in validated questionnaires⁹

human trialBremelanotide was approved by the FDA in 2019 for treatment of generalized hypoactive sexual desire disorder¹⁰

human trialBremelanotide has demonstrated efficacy and safety for HSDD¹³

human trialThe clinical development program comprised 3500 subjects in 43 completed studies¹⁴

human trialParticipants preferred placebo, measured by the combination of both completing a clinical trial and electing to participate in the follow-up open-label study: OR = 0.30, 95% CI = .24-.38, NNH: 4¹⁵

human trialBremelanotide demonstrates significant improvement in desire and a significant decrease in distress related to lack of desire¹⁶

human trialWomen taking bremelanotide had statistically significant increases in sexual desire (study 301: 0.30, P<.001; study 302: 0.42, P<.001; integrated studies 0.35, P<.001) compared with placebo¹⁸

human trialWomen taking bremelanotide had statistically significant reductions in distress related to low sexual desire (study 301: -0.37, P<.001; study 302: -0.29, P=.005; integrated studies -0.33, P<.001) compared with placebo¹⁸

human trialA double-blind, placebo-controlled study tested intranasal PT-141 in healthy men and those responsive to Viagra²³

human trialRigiScan measurements showed clear erectile responses at doses above 7 mg compared with placebo²³

human trialA separate Phase IIB at-home study measured erectile function using the International Index of Erectile Function questionnaire with dose-dependent improvements across 10 mg, 15 mg, and 20 mg doses compared with placebo²³

human trialAmong men who had failed adequate Viagra trials, 33.5% achieved a positive clinical response with PT-141 versus 8.5% on placebo²³

human trialMen on PT-141 reported better sexual self-confidence and relationship satisfaction on the Self-Esteem and Relationship scale²³

human trialA randomized crossover study examined PT-141 combined with sildenafil in 32 men with erectile dysfunction, showing co-administration increased the duration of erectile activity by roughly fivefold compared with sildenafil alone²³

human trialRigiScan monitoring showed the combination produced more than five times longer duration of base rigidity during 6-hour observation periods with visual sexual stimulation²³

human trialA double-blind, placebo-controlled study tested intranasal PT-141 in healthy men and those responsive to Viagra with RigiScan measurements showing clear erectile responses at doses above 7 mg compared with placebo²⁴

human trialA Phase IIB at-home study measured erectile function using the International Index of Erectile Function questionnaire with men showing dose-dependent improvements across 10 mg, 15 mg, and 20 mg doses compared with placebo²⁴

human trialAmong men who had failed adequate Viagra trials, 33.5% achieved a positive clinical response with PT-141 versus 8.5% on placebo²⁴

human trialMen who failed Viagra reported better sexual self-confidence and relationship satisfaction on the Self-Esteem and Relationship scale with PT-141²⁴

human trialA randomized crossover study examined PT-141 combined with sildenafil in 32 men with erectile dysfunction and found co-administration increased the duration of erectile activity by roughly fivefold compared with sildenafil alone²⁴

human trialRigiScan monitoring showed the combination produced more than five times longer duration of base rigidity during 6-hour observation periods with visual sexual stimulation²⁴

human studyStudies showed improvements in desire, arousal, and orgasm scores when 1.75 mg of bremelanotide was administered before sexual activity compared to a placebo¹¹

human studyA phase IIb trial in patients with ED was completed by Palatin in September 2003²⁰

human studyPalatin planned to start phase III trials in early 2005²⁰

expert opinionBremelanotide has been recently approved by the FDA to treat HSDD²

expert opinionThe overall clinical benefit appears to be modest⁹

expert opinionPT-141 (Bremelanotide) is the first FDA-approved peptide that works through your brain to reignite sexual desire²²

expert opinionFDA approval based on significant improvements in desire scores²²

expert opinionOne of the most thoroughly studied sexual health peptides, with Phase 3 trials, FDA approval, and long-term safety data²²

expert opinionPT-141 has FDA approval for female sexual dysfunction and shows promise for off-label use in men based on clinical trial data²³

expert opinionPT-141 has FDA approval for female sexual dysfunction²⁴

expert opinionPT-141 shows promise for off-label use in men based on clinical trial data²⁴

expert opinionbremelanotide has FDA approval for acquired, generalized HSDD in premenopausal women²⁵

expert opinionBremelanotide is the first and only melanocortin receptor agonist approved specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women²⁶

expert opinionClinical trials demonstrated statistically significant improvements in sexual desire and decreases in distress related to low desire compared to placebo²⁶

expert opinionPatients report effects lasting 6–24 hours post-injection, despite the relatively short plasma half-life of 2.7 hours²⁶

expert opinionClinical trial response rates showed approximately 25% of participants achieving clinically meaningful improvement in desire scores versus 17% on placebo²⁶

expert opinionFDA approval for bremelanotide occurred in 2019²⁶

expert opinionClinical trials have demonstrated the efficacy of Bremelanotide acetate in improving sexual desire and reducing distress associated with HSDD²⁷

animalAnimal studies show PT-141 increases dopamine turnover in the ventral tegmental area and nucleus accumbens, both linked to sexual motivation²⁴

expert opinionBremelanotide is a melanocortin receptor agonist²

expert opinionThe pathophysiology of HSDD is thought to be centered around inhibitory and excitatory hormones, neurotransmitters, and specific brain anatomy²

expert opinionBremelanotide functions as a melanocortin receptor agonist with high affinity for melanocortin type 4 receptors (MC4R), which are thought to modulate brain pathways involved in sexual response⁸

expert opinionIn premenopausal women with hypoactive sexual desire disorder (HSDD), melanocortin receptor agonist bremelanotide (Vyleesi) has been hypothesized to trigger excitatory brain pathways⁹

expert opinionBremelanotide is a melanocortin receptor agonist¹¹

expert opinionBremelanotide is a synthetic heptapeptide and melanocortin receptor (MCR) agonist¹⁷

expert opinionWorks through brain pathways rather than just boosting blood flow like traditional ED medications²²

expert opinionDirectly activates brain pathways controlling sexual motivation²²

expert opinionPT-141, also known as bremelanotide, is a research peptide that targets brain pathways that regulate sexual desire and arousal²³

expert opinionPT-141 works on central circuits that drive motivation and erectile response, rather than acting directly on blood vessels in the penis like common erectile dysfunction medications²³

expert opinionPT-141 binds to melanocortin-3 and melanocortin-4 receptors concentrated in the hypothalamus, especially the medial preoptic area that governs male sexual behavior²³

expert opinionDopamine acts as an excitatory neurotransmitter that drives sexual desire, motivation, and reward processing²³

expert opinionPT-141, also known as bremelanotide, is a research peptide that targets brain pathways that regulate sexual desire and arousal²⁴

expert opinionPT-141 works on central circuits that drive motivation and erectile response instead of acting directly on blood vessels in the penis like common erectile dysfunction medications²⁴

expert opinionPT-141 binds to melanocortin-3 and melanocortin-4 receptors concentrated in the hypothalamus, especially the medial preoptic area that governs male sexual behavior²⁴

expert opinionPT-141 receptor activation triggers dopamine release in key brain regions²⁴

expert opinionPT-141 does not rely on intact peripheral blood vessels or nitric oxide production, which may offer an advantage in certain medical conditions²⁴

expert opinionPT-141 (bremelanotide) is a synthetic melanocortin receptor agonist²⁵

expert opinionbremelanotide acts through central melanocortin signalling²⁵

expert opinionbremelanotide is not interchangeable with phosphodiesterase-pathway drugs²⁵

expert opinionBremelanotide activates melanocortin receptor pathways in the central nervous system²⁵

expert opinionBremelanotide acts centrally on MC3R and MC4R melanocortin receptors in the hypothalamus to influence sexual desire pathways directly²⁶

expert opinionBremelanotide is a cyclic heptapeptide melanocortin receptor agonist that activates MC3R and MC4R receptors in the central nervous system²⁶

expert opinionBremelanotide is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) with modifications that enhance receptor selectivity and bioavailability²⁶

expert opinionBremelanotide's selectivity for MC3R and MC4R (rather than MC1R involved in pigmentation or MC2R involved in adrenal function) allows it to influence sexual desire pathways while minimizing off-target effects²⁶

expert opinionBremelanotide binds to melanocortin receptors MC3R and MC4R located primarily in the central nervous system, particularly within hypothalamic nuclei that regulate sexual behavior, motivation, and reward pathways²⁶

expert opinionBremelanotide activates these receptors triggering intracellular signaling cascades involving cyclic adenosine monophosphate (cAMP) and downstream effectors that modulate neurotransmitter release including dopamine²⁶

expert opinionBremelanotide acetate is a melanocortin receptor agonist²⁷

expert opinionIt primarily targets the melanocortin-4 receptor (MC4R) found in the central nervous system²⁷

expert opinionBy activating MC4R, Bremelanotide influences pathways in the brain associated with sexual desire and arousal²⁷

expert opinionBremelanotide acetate crosses the blood-brain barrier and stimulates the release of neurochemicals that regulate sexual motivation²⁷

expert opinionThis activation results in increased dopamine levels in the brain²⁷

expert opinionBremelanotide also affects serotonin levels²⁷

expert opinionBremelanotide does not exert its effects through the vascular system, unlike some other treatments for sexual dysfunction that rely on vasodilation²⁷

expert opinionMultiple hormones and neurotransmitters likely participate in a dual-control model to balance excitation and inhibition of sexual desire²⁸

theoreticalMC4R activation in the hypothalamus, dopaminergic pathway modulation, and effects on brain regions involved in sexual motivation⁷

theoreticalThe majority of MC4R expression occurs in dopamine neurons within the ventral tegmental area⁸

theoreticalRegulation of central melanocortin signaling may enhance sexual desire⁹

human trialDosing regimen: 1.75 mg subcutaneous injection in the abdomen or thigh, administered at least 45 minutes before anticipated sexual activity, maximum frequency one dose per 24 hours, monthly limit no more than 8 doses per month⁸

human trialTreatment should be discontinued if no improvement occurs after 8 weeks of use⁸

human trialIn phase 3 studies, subjects took bremelanotide for up to 18 months¹⁴

human trialBremelanotide is a subcutaneous injection that can be administered as needed approximately 45 minutes prior to sexual activity¹⁶

human trialDosing regimen: One injection, as needed, not to exceed more than one dose in a 24-hour period and not to exceed 8 doses per month¹⁷

human trialBremelanotide is a self-administered, on-demand subcutaneous therapy¹⁹

expert opinionBremelanotide is administered intranasally or as a subcutaneous injection²

expert opinionThe recommended dosage of bremelanotide is 1.75 mg injected subcutaneously in the abdomen or thigh at least 45 min before sexual activity²

expert opinionBremelanotide is administered intranasally or as a subcutaneous injection¹¹

expert opinionThe recommended dosage of bremelanotide is 1.75 mg injected subcutaneously in the abdomen or thigh at least 45 min before sexual activity¹¹

expert opinionPrescribing guidelines recommend no more than 1 dose in 24 hours and no more than 8 doses per month¹⁶

expert opinionIndividuals should discontinue use after 8 weeks without benefit¹⁶

expert opinionAdministered by subcutaneous injection into fatty layer under the skin²²

expert opinionStarting dose is 1 mg, used as needed approximately 45 minutes before sexual activity with maximum frequency of once per 24 hours²²

expert opinionLower 1 mg trial dose used in practice to gauge nausea tolerance before moving to FDA dose²²

expert opinionSubcutaneous injection remains the preferred route for PT-141 administration²³

expert opinionTypical doses range from 0.5 mg to 2.0 mg per administration²³

expert opinionMost practitioners start at conservative 0.5 to 0.75 mg doses to assess individual tolerance²³

expert opinionMaintenance dosing usually falls between 1.0 and 1.75 mg per injection²³

expert opinionSingle doses above 2.0 mg are not recommended because higher amounts raise adverse events without proportional benefit²³

expert opinionAdminister PT-141 30 to 60 minutes before planned sexual activity to allow time for peak plasma concentration²³

expert opinionLimit dosing frequency to once every 24 hours or preferably 2-3 times per week to maintain responsiveness and reduce the chance of side effect accumulation²³

expert opinionSubcutaneous injection remains the preferred route with typical doses ranging from 0.5 mg to 2.0 mg per administration²⁴

expert opinionMost practitioners start at conservative 0.5 to 0.75 mg doses to assess individual tolerance²⁴

expert opinionMaintenance dosing usually falls between 1.0 and 1.75 mg per injection²⁴

expert opinionSingle doses above 2.0 mg are not recommended because higher amounts raise adverse events without proportional benefit²⁴

expert opinionAdminister PT-141 30 to 60 minutes before planned sexual activity²⁴

expert opinionLimit dosing frequency to once every 24 hours or preferably 2-3 times per week to maintain responsiveness and reduce the chance of side effect accumulation²⁴

expert opinionbremelanotide has a formal FDA label and defined human dosing information²⁵

expert opinionBremelanotide is administered as a subcutaneous injection²⁶

human trialMedian time to first erection was 30 minutes, with elimination half-life ranging from 1.85 to 2.09 hours²³

human trialMedian time to first erection was 30 minutes with elimination half-life ranging from 1.85 to 2.09 hours²⁴

expert opinionWorks within 45-60 minutes and lasts several hours²²

expert opinionHigh bioavailability with subcutaneous injection²²

expert opinionTime-to-peak of approximately 30 minutes to one hour creates a narrow but workable window for scheduling²³

expert opinionTherapeutic effects persist for 4 to 6 hours after administration based on pharmacokinetic data²³

expert opinionTime-to-peak of approximately 30 minutes to one hour creates a narrow but workable window for scheduling²⁴

expert opinionTherapeutic effects persist for 4 to 6 hours after administration based on pharmacokinetic data²⁴

expert opinionBremelanotide has a half-life of approximately 2.7 hours following subcutaneous administration, with peak plasma concentrations reached within 1 hour²⁶

expert opinionBremelanotide undergoes hydrolytic degradation rather than hepatic metabolism²⁶

expert opinionAfter subcutaneous administration, the peptide is rapidly absorbed into the bloodstream²⁷

expert opinionIt reaches peak plasma concentrations within about one hour²⁷

expert opinionThe half-life of Bremelanotide is approximately 2.7 hours²⁷

human trialNausea improved for most patients with the second dose⁴

human trialMost common adverse reactions (incidence > 4%) are nausea, flushing, injection site reactions, headache, and vomiting⁴

human trialTransient increase in blood pressure and decrease in heart rate occurs after each dose and usually resolves within 12 hours⁵

human trialFocal hyperpigmentation reported by 1% of patients who received up to 8 doses per month, including involvement of the face, gingiva and breasts⁵

human trialHigher risk of hyperpigmentation in patients with darker skin and with daily dosing⁵

human trialNausea reported by 40% of patients who received up to 8 monthly doses, requiring anti-emetic therapy in 13% of patients and leading to premature discontinuation for 8% of patients⁵

human trialNausea improved for most patients with the second dose⁵

human trialMost common adverse reactions (incidence > 4%) are nausea, flushing, injection site reactions, headache, and vomiting⁵

human trialContraindicated in uncontrolled hypertension or known cardiovascular disease⁵

human trialBremelanotide demonstrates favorable safety profile in treating hypoactive sexual desire disorder in premenopausal women⁶

human trialThe most common treatment-emergent adverse events considered related to study drug were nausea (40.4%), flushing (20.6%), and headache (12.0%)⁶

human trialThe only severe treatment-emergent adverse event experienced by more than one participant in both studies was nausea during the open-label extension⁶

human trialNo new safety signals were observed during the 52-week open-label extension⁶

human trialDemonstrates favorable overall safety profile with primarily mild to moderate adverse events across the bremelanotide clinical development program⁷

human trialHigh nausea rate reported as a limitation in Phase 3 trials⁷

human trialNausea occurred in 40.0% of Phase 3 trial participants (vs 1.3% placebo) and was the most common reason for discontinuation⁸

human trialFlushing occurred in 20.3% of Phase 3 trial participants (vs 1.3% placebo)⁸

human trialHeadache occurred in 11.3% of Phase 3 trial participants (vs 1.9% placebo)⁸

human trialInjection site reactions occurred in 5.4% of Phase 3 trial participants (vs 0.5% placebo)⁸

human trialTransient increases in blood pressure and decreases in heart rate occur after each dose and typically resolve within 12 hours post-injection⁸

human trialFocal hyperpigmentation can occur on face, gingiva, and breasts, particularly in patients with darker skin, with risk increasing with daily use (occurred in >33% with 16 consecutive daily doses)⁸

human trialBremelanotide appears to be moderately safe and well-tolerated⁹

human trialThe most common adverse reaction is nausea (40%)⁹

human trialThe FDA approval of bremelanotide in 2019 demonstrates the safety of the melanocortin peptide class¹⁰

human trialNausea occurred in 40.0% of bremelanotide group versus 1.3% in placebo group in integrated double-blind portion of phase 3 studies¹⁴

human trialFlushing occurred in 20.3% of bremelanotide group versus 1.3% in placebo group¹⁴

human trialHeadache occurred in 11.3% of bremelanotide group versus 1.9% in placebo group¹⁴

human trialInjection site reactions occurred in 5.4% of bremelanotide group versus 0.5% in placebo group¹⁴

human trialNausea was the most common reason for bremelanotide discontinuation¹⁴

human trialThere were no deaths in the clinical development program¹⁴

human trialFocal hyperpigmentation was rare when dosed in accordance with label recommendations but occurred in more than one-third of subjects following up to 16 consecutive daily dosings¹⁴

human trialSmall and transient but statistically significant blood pressure increases were observed during ambulatory blood pressure monitoring¹⁴

human trialBremelanotide should be used with caution in patients at risk of cardiovascular disease¹⁴

human trialBlood pressure should be well controlled during bremelanotide treatment¹⁴

human trialAdverse event-induced study discontinuation was substantially higher on bremelanotide: OR = 11.98, 95% CI = 3.74-38.37, NNH: 6¹⁵

human trialThe most common adverse effects include nausea (39.9%), facial flushing (20.4%), and headache (11%)¹⁶

human trialBremelanotide is safe and has limited drug-drug interactions, including no clinically significant interactions with ethanol¹⁶

human trialPatients taking bremelanotide experienced more nausea, flushing, and headache (10% or more in both studies) compared with placebo¹⁸

human trialMost treatment-emergent adverse events were mild or moderate in intensity¹⁸

human trialThe combination introduced no new serious adverse events²³

human trialThe combination of PT-141 and sildenafil introduced no new serious adverse events²⁴

human study52-week maximum follow-up in open-label extension safety studies⁷

human trialPT-141 (bremelanotide/Vyleesi) is FDA-approved exclusively for treating hypoactive sexual desire disorder (HSDD) in premenopausal women with acquired, generalized low sexual desire causing marked distress⁸

human trialBremelanotide is a psychoactive agent indicated for the treatment of generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women¹²

human trialBremelanotide is listed among available treatments for hypoactive sexual desire disorder (HSDD)¹³

human trialBremelanotide is a melanocortin receptor agonist FDA-approved for treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder¹⁴

human trialBremelanotide was studied in two 24-week Phase III trials for treating hypoactive sexual desire disorder (HSDD) in women¹⁵

human trialVyleesi (bremelanotide) was approved for the treatment of premenopausal women with acquired, general hypoactive sexual desire disorder (HSDD)¹⁷

human trialBremelanotide 1.75 mg administered subcutaneously as needed was evaluated for safety and efficacy in premenopausal women with hypoactive sexual desire disorder¹⁸

human trialBremelanotide (Vyleesi™) is a melanocortin receptor agonist approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)¹⁹

human studyBremelanotide is the second Food and Drug Administration-approved medication for the treatment of HSDD¹⁶

human studyPT-141 is being developed as a nasal spray for the potential treatment of erectile dysfunction (ED)²⁰

human studyPT-141 is being developed for the potential treatment of female sexual dysfunction²⁰

expert opinionHypoactive sexual desire disorder (HSDD) is a persistent deficiency or absence of sexual fantasies and desire resulting in significant distress or interpersonal difficulty²

expert opinionBremelanotide has been recently approved by the FDA to treat HSDD¹¹

expert opinionProvides on-demand use without daily dosing commitment²²

expert opinionBremelanotide acetate was developed for its potential therapeutic benefits, particularly in addressing hypoactive sexual desire disorder (HSDD) in premenopausal women²⁷

expert opinionNearly half of women in the United States report problems with sexual function²⁸

expert opinionHSDD is characterized by a deficiency of sexual thoughts, feelings, or receptiveness to sexual stimulation that has been present for at least 6 months, causes personal distress, and is not due to another medical condition²⁸

expert opinionBremelanotide is a recently approved medication for HSDD²⁸

expert opinionPT-141 is a synthetic cyclic peptide²⁵

expert opinionPT-141 is a heptapeptide²⁵

anecdotalThe peptide was discovered by accident during research on tanning compounds when a scientist experienced unexpected erectile effects²³

anecdotalThe peptide was discovered by accident during research on tanning compounds when a scientist experienced unexpected erectile effects²⁴